Navigation Links
MDA's Board Chairman Testifies Before US Senate Subcommittee to Advocate for Newborn Screening
Date:9/27/2013

Tucson, AZ (PRWEB) September 27, 2013

Pediatrician and medical geneticist R. Rodney Howell, who chairs MDA's Board of Directors, testified Thursday before the Subcommittee on Children and Families of the U.S. Senate Committee on Health, Education, Labor & Pensions to advocate for passage of the Newborn Screening Saves Lives Reauthorization Act of 2013 (S. 1417).

Howell emphasized that:

  •     conditions that can be detected at birth for which there are emerging therapies should be given priority in the review process for inclusion in the list of recommended newborn screening tests;
  •     priority review will not reduce the scientific rigor of the review process; and
  •     newborn screening reduces the overall cost of illness (sometimes called "burden of disease") for the conditions involved.

"It is important to emphasize that the conditions that are included on the newborn screening panel all result in serious medical complications (e.g., developmental delay) and/or death if not recognized early," Howell told the subcommittee. "All children with these conditions benefit from early diagnosis and treatment."

Three disorders in MDA's program are or may become candidates for addition to the Recommended Uniform Screening Panel (RUSP.) Pompe disease was presented to the Advisory Committee for possible inclusion in the RUSP in January 2013, and the Advisory Committee has recommended that it be added to the RUSP. Spinal muscular atrophy (SMA) was nominated several years ago but not deemed ready for full review by the Advisory Committee; a pilot for SMA newborn screening is under way. In February 2013, scientific information about the feasibility of newborn screening for Duchenne muscular dystrophy (DMD) was presented to the Committee.

A video of the Sept. 26, 2013, Senate subcommittee hearing is available.

To support the Newborn Screening Saves Lives Act, take five minutes to contact your U.S. senator here: mda.org/advocacy/get-involved/legislative-alerts.

About MDA

The Muscular Dystrophy Association is the world’s leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement. Visit mda.org and follow us at facebook.com/MDAnational and @MDAnews.

-MDA-

Read the full story at http://www.prweb.com/releases/2013/9/prweb11173040.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Eighth Annual Tradition of Hope Gala to Support MDA's Augie's Quest
2. PreCheck VP of Compliance, Vu T. Do, Elected to NAPBS® Board of Directors
3. PreDiabetes Centers Medical Advisory Board Meets in Austin
4. Board Certified Dermatologist Reveals The Best Time Of The Year For Laser Treatments
5. ThermalDrain™ Synthetic Protection Board Chosen as Finalist for 2013 RISE® Durable Product Awards
6. Excelsius Surgical, LLC Names Fred Moll and Rich Grant to Board of Directors
7. University of Western States Board Elects Executive Committee Members
8. Boyd “Rainmaker” Melson, Professional Athlete and Advocate for Spinal Cord Injury Treatment, Signs on as Advisory Board Member of Store-A-Tooth™ Dental Stem Cell Banking
9. 20 Nursing Students Awarded 2013 APNA Board of Directors Student Scholarships by the American Psychiatric Nurses Association
10. Health Data Intelligence Delivers a Critical Patient Safety and Infection Control Surveillance Tool with the Introduction of the Hospital Complications Dashboard
11. New Online Tote Board to Give Supporters Fundraising Updates During MDA Telethon This Sunday
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology: